Protagonist Therapeutics

News

Takeda scores with polycythemia vera drug in phase 3 trial

A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.

News

J&J plots filings after psoriasis drug clears phase 3 test

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial.

News

Takeda grabs late-stage haematology drug from Protagonist

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics.

Takeda scores with polycythemia vera drug in phase 3 trial

J&J plots filings after psoriasis drug clears phase 3 test

Takeda grabs late-stage haematology drug from Protagonist

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

Protagonist Therapeutics

Editor's Picks